Omicron risk remains 'very high’—WHO | Inquirer News
Close  

Omicron risk remains ‘very high’—WHO

/ 12:57 PM December 29, 2021
\Syringes with needles are seen in front of a displayed stock graph and words "Omicron SARS-CoV-2" in this illustration taken

Syringes with needles are seen in front of a displayed stock graph and words “Omicron SARS-CoV-2” in this illustration taken, Nov. 27, 2021. (REUTERS/Dado Ruvic/Illustration)

GENEVA — The risk posed by the Omicron variant is still “very high”, the World Health Organization said Wednesday, after Covid-19 case numbers shot up by 11 percent globally last week.

Omicron is behind rapid virus spikes in several countries, including those where it has already overtaken the previously-dominant Delta variant, the WHO said in its Covid-19 weekly epidemiological update.

ADVERTISEMENT

“The overall risk related to the new variant of concern Omicron remains very high,” the UN health agency said.

“Consistent evidence shows that the Omicron variant has a growth advantage over the Delta variant with a doubling time of two to three days and rapid increases in the incidence of cases is seen in a number of countries,” including Britain and the United States, where it has become the dominant variant.

FEATURED STORIES

“The rapid growth rate is likely to be a combination of both immune evasion and intrinsic increased transmissibility of the Omicron variant.”

However, the WHO highlighted the 29 percent decrease in the incidence of cases observed in South Africa — the country which first reported the variant to the WHO on November 24.

It said early data from Britain, South Africa and Denmark — which currently has the world’s highest rate of infection per person — suggested there was a reduced risk of hospitalization for Omicron compared to Delta.

However, further data was needed to understand Omicron’s severity in terms of clinical markers, including the use of oxygen, mechanical ventilation and death.

More data was also required on how the severity might be being impacted by previous Covid infection, or vaccination.

“It is also expected that corticosteroids and interleukin 6 receptor blockers will remain effective in the management of patients with severe disease,” the WHO said.

“However, preliminary data suggest that monoclonal antibodies may be less able to neutralize the Omicron variant.”

ADVERTISEMENT

Rise in cases

The WHO said that in the week ending Sunday, following a gradual increase since October, the global number of new cases rose by 11 percent compared to the previous week, while the number of new deaths dipped by four percent.

“This corresponds to just under five million new cases and over 44,000 new deaths,” the Geneva-based organization said.

The highest numbers of new cases were reported from the United States, Britain, France and Italy.

RELATED STORIES

WHO: Omicron ‘likely’ to replace Delta variant
WHO: Omicron spreading faster than Delta

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19, Health, Omicron variant, WHO
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.